Innovation

Big Digital Energy's joint venture has signed a non-binding letter of intent with Tensor IQ to develop a 17 MW AI and HPC

Femasys and UNC Health have partnered to offer in-office fertility diagnostics and intratubal insemination across the academic system's statewide OB/GYN locations.

Nuwellis will co-promote Atrility's FDA-cleared cardiac pacing monitor across 14 US states, with an option to become exclusive national distributor.

APL-10456 induced broad cross-reactive T cell responses against all three rhinovirus species in a 144-participant Phase 1 trial, with no serious adverse

Tracxn data show UK consumer robotics attracted $258M year-to-date in 2026, with Cambridge accounting for nearly 60% of all-time funding at $1

The NASDAQ-listed women's health company said the modular submission route lets regulators review key components before final FINALE trial data are available.

The FDA has authorised the first standalone robotic phlebotomy device, cleared via De Novo pathway, to address a growing shortage of trained phlebotomists.

Vascudyne's acellular tissue-engineered vessel maintained full patency for 18 months in a large-animal CABG model, with anticoagulation stopped at six months.

Sight Sciences says TearCare is now the first MGD treatment indicated to improve meibomian gland function in evaporative dry eye patients.

Imamu Tomlinson, CEO of the $2.6bn physician-owned partnership, argues burnout is a systemic failure, not an individual one.

Tracxn data shows five companies absorbed 84% of capital raised, with London capturing 98% of the national total.

Deep Origin's physics-augmented virtual screening framework achieved a 30.6% hit rate on CD73, against a 0.3% baseline from a prior AI

Aetna has recognised both implant-free MIGS devices as medically necessary for mild-to-moderate open-angle glaucoma, completing major US payer coverage for Sight

Senseonics lifted its full-year 2026 revenue target to $62–66 million after record quarterly revenue and gross margins beat its own guided range.

Early observations from MiNK's randomised Phase 2 in severe hypoxemic pneumonia showed treated patients alive, afebrile and off ventilator support at Day 28.

The French medtech firm will use the growth loan to commercialise TAVIpilot, its FDA-cleared AI-guided software for transcatheter aortic valve procedures.

Clearmind Medicine's Phase I/II trial of CMND-100 can progress to patient cohorts after its safety board unanimously approved advancement following a clean

The MIT spinout will use five-year federal funding to develop a magnetic robotic navigation platform for autonomous endovascular thrombectomy.

The Nasdaq-listed cardiac monitoring company will pay $237.5m in cash and $50m in stock for the wearable biosensor firm.

Stockholm-based Sigrid Therapeutics has made its gut-local metabolic health products available to over 125,000 US practitioners via Fullscript.